Helping people in need !!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ATHX has added a new presentation to its website ..
https://s23.q4cdn.com/674737627/files/images/2020/10-06-2020-ATHX-Investor-Presentation-October.pptx.pdf
T2 Job offers Amsterdam..
https://www.indeed.nl/vacatures?q=t2%20biosystems&l=Amsterda… We are looking for a driven, customer-focused Technical Service Engineer (EU) to join our growing global commercial organization. This individual will serve as the technical lead for installation and service for all T2 Biosystems instrumentation. This role will also directly support our distribution partners through co-travels, continued product training and escalations. In addition to those responsibilities, the Technical Service Engineer will also provide ongoing technical service and operator training at customer sites....GOOD LUCK LONGS
T2 biosystems der game changer?! | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1318484-591-600/t2-biosystems-game-changer#neuster_beitrag
On the bright side ATHX partner Healios PPS just hit new 52 week High on very heavy volume, news should follow .. GOOD LUCK LONGS
Last night earnings presentation, Healios CEO Hardy Kagimoto talks about their ARDS program and states, “Building on the Athersys data from the United States and anticipated data from our study, Orphan Status, and the complete absence of an effective treatment for these patients, we expect to seek approval for this product next year”
*Enrollment complete anytime.
*Data available 6 weeks after enrollment
*preparations for regulatory submission for approval already underway
*expedited review with Orphan
ATHX will receive success-based regulatory filing and approval milestones up to $50 million next year. Then they will start to receive tiered royalties on product sales, starting in the low double digits and increasing incrementally into the high teens or potentially higher depending on net sales levels and other factors. Sales milestones up to $175 million down the road.
This is just ARDS. Stroke completes enrollment soon as well and has all the same payments, with a much bigger target market .. GOOD LUCK LONGS
T2 has a job posting for an installation technician in Burbank CA. Presumably, they don't anticipate hiring a guy so they can look after a 4 machine installation. Of all the the places in CA, why do you suppose they picked Burbank ... Hellloooooo GOOD LUCK LONGS
There was 1 block of over 960,000 traded at 4:08 @2.18 after hrs. and another 140K minutes later. Hopefully NEWS follow's it's way overdue and HEALIOS is close making a new 52 week high. GOOD LUCK LONGS
An old classmate of GVB...I would love to see GVB reach out to this individual and have a conversation about Multistem. If you don't have that rigour, the well-designed rigorously conducted, ideally double-blind, randomized controlled trials to minimize or even eliminate that bias, then you can't get a robust answer to these critical questions. Larry Tsai Global Head of Respiratory and Rheumatology Product Development, Roche Genentech Stanford University 1989-1993)"One of the things that makes this company special is that everyone really believes in this mission of trying to bring transformative medications to patients with unmet medical needs. It's hard to argue that there's more pressing medical need right now in the world than COVID-19."
https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/larry-tsai.htm
T2 keeps adding to run on the same machine should be an attractive business model for any of the big players in the lab test business. They even delve into some rare but critical diseases and Bio-threat detection (ripe for defense contracts). Some strong quarterly reports, this could turn into a merger or a buyout .. GOOD LUCK LONGS
This #SepsisAwareness month, we would like to give a big thank you from T2 Biosystems to all of the healthcare workers that inspire us daily. Join us tomorrow at The Sepsis Alliance Summit! #SepsisSummit #T2SAM2020 #SAM2020 #SepsisAlliance https://t.co/CjvMWqga86
— T2 Biosystems (@T2Bio) September 15, 2020
Published: Sep 15, 2020 By Chelsea Weidman Burke ...
Stem Cells Helps COVID-19 and ARDS Patients Breathe Easier ..They should be hearing news from Healios PMDA approval coming for Covid Induced ARDS .. GOOD LUCK LONGS
SYNJ IS A GREAT COMPANY FOR YOU TO LOSE MONEY !!!!!!!!!!!!
YOU GOT TO LOVE SOME OF THESE MODERATORS That Moderate THIS SOOOOOO CALLED COMPANY ... THEY DON'T HAVE A CLUE !!!!
They attack the MESSAGE instead the BEST CEO OF ALLLLLLL TIMES that's be GIVING them the K Y which they seem to LOVE IT !!!!! If you live with a CRIPPLE you will learn to LIMP. I guess The MODERATES on this site LIKE THEIR names LISTED like they are so important to this so CALLED Co. EVENTUALLY they will realize that MISTAKES are MEANT for LEARNING not REPEATING. You live and learn at any RATE .. YOU MOVE ON NOT THIS GROUP we are allll born CRAZY. Some of us remain STUCK that way !!!!!!
Eric Jenkins, senior medical director and head of clinical operations at Athersys, says one of the advantages of MAPCs over MSCs is that they can be multiplied in much greater volume in the lab. This provides a level of consistency that will help win regulatory approval. “Being able to create millions of doses from a single donor collection permits you to develop a really well characterised, standardised and stable product on a commercial scale,” he says. “Having to frequently collect and culture bone marrow is problematic, because essentially it is a new product every time.”
https://www.reddit.com/r/ATHX/comments/iszmis/researchers_gain_head_start_in_coronavirus/?utm_source=share&utm_medium=mweb
Friday's news seems great for the CEO
Athersys CEO 'confident' drug will deliver in COVID-19, Spectrum News 1 reports Athersys has focused on creating a stem cell therapy for people suffering from ARDS, the leading cause of death among COVID-19 infection patients, and CEO Gil Van Bokkelen is confident that the company's patented MultiStem therapy will deliver in COVID, Spectrum News 1's Micaela Marshall reports. In May, University Hospitals became the first site for a "MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome" clinical trial, and Van Bokkelen says "It's been going well. I mean, UH is very active. We got a number of things that are going on that basically give us a lot of hope for this."
Read more at:
https://thefly.com/n.php?id=3159301
Also Behind the scenes the pieces are coming together. Macleod, SIFU, MACOVIA... Posted by u/athersys on Reddit 3 days ago
Athersys files for new Trademark for SIFU
Athersys files for new trademark for SIFU on 9/1:
https://uspto.report/TM/90152411
It also has previously filed for the trademark illustration for SIFU here:
https://uspto.report/TM/88425115
I can see the SIFU development, manufacturing and rollout costs being very high and is another reason Gil is bringing in an EU partner, IMO. This is a type of device technology that can also be licensed out bringing in additional revenue for the company.
SIFU™ trademark registration is intended to cover the categories of medical machines, namely, medical apparatus in the nature of a cryogenic storage and delivery apparatus specially adapted for cryogenic freezing, thawing and dispensing biologic product for medical purposes .. GOOD LUCK LONGS
There's been a increase Number of Institutions Holding Shares ...
https://finance.yahoo.com/quote/TTOO/holders?p=TTOO
Athersys has the best opportunity to take a cellular therapy to market in ARDS. They have the most complete data sets in this indication.
1. MUST-ARDS 36 total patients. 26 given MultiStem in ARDS from a variety of causes, 10 placebo
2. ONE-BRIDGE 35 total patients. 20 given MultiStem in ARDS caused by pneumonia, 5 given MultiStem
in COVID ARDS, 10 placebo
3. MACOVIA multiple patients given MultiStem from COVID ARDS
Fast Track in US and Orphan Status in Japan.
Athersys partner Healios about to complete enrollment and file for approval in early 2021
With today's news and all the accomplishments going forward this is a Screaming BUY .. GOOD LUCK LONGS
https://www.t2biosystems.com/news-resources-ous/in-the-news-ous/
With all the good news and the price let down. It seems everyone focused on the Covid 19 test panel- which in itself is a good thing for T2 to have. However, that is not their core business to the slightest, it's just an opportunity for them to sell more of the T2 machines, so that they can have a good number of hospitals hooked on to it. They make more money on the slew of test panels that can run on the same machine, from early diagnosing sepsis (including on critically ill covid 19 patients) to testing for many other infectious diseases and antibiotic resistance screenings.Then the big elephant in the room that no one is talking about is the "NEW" test panel they are developing for Bio-threats (which they have to still get FDA approval on and their research is supported by Govt funding). Think about T2 getting a Defense contract for that panel when it comes out. The bio-threat panel alone will make them huge, as it is a big unmet need and when thinking of the many crazies going on around the world; if approved, such a quick test for those possible biological weapon pathogens will be a game changer....GOOD LUCK LONGS
For those of you who are interested to read about Multistem.
The MultiStem clinical product is developed from a special class of stem cells called Multipotent Adult Progenitor Cells, or MAPC®.
1. Preterm Brain Injury, Antenatal Triggers, and Therapeutics:
https://www.mdpi.com/2073-4409/9/8/1871
2. Safety and Efficacy of Stem Cell Therapy in Patients With Ischemic Stroke [MAPC treatment results]:
At 1 year: mRS ≤2 achieved in 51% of treatment group vs 44% of control; NIHSS improvement of ≥75% in 49% of treatment group vs 46% of control; Excellent outcome achieved in 23% of treatment vs 8% of control (p= 0·0206) [Excellent outcome: composite of mRS ≤1, NIHSS ≤1, and BI ≥95]
https://www.cureus.com/articles/38405-safety-and-efficacy-of-stem-cell-therapy-in-patients-with-ischemic-stroke
3. The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers:
There was no detrimental effect on perfusion flow parameters on infusion of MAPC cells by either route. Three out of six livers met established criteria for organ viability. 35-plex multiplex analysis of perfusate yielded 13 positive targets, 9 of which appeared to be related to the infusion of MAPC cells. Proteomic analysis revealed 295 unique proteins in the perfusate from time-points following the infusion of cellular therapy, many of which have strong links to MAPC cells and mesenchymal stem cells in the literature. Functional enrichment analysis demonstrated their immunomodulatory potential. MAPC cells appear to secrete a host of soluble factors that would have anti-inflammatory and immunomodulatory benefits in a human model of liver transplantation.
https://www.frontiersin.org/articles/10.3389/fimmu.2020.01226/full
4. Human MAP cell-conditioned medium improves wound healing through modulating inflammation and angiogenesis:
MAPC cells can have an important effect on cutaneous wound healing by affecting skin cell proliferation and migration, balancing inflammation and improving the formation of extracellular matrix and angiogenesis. Development of stem cell-free therapy for the treatment of wounds may be a more clinically translatable approach for improving healing outcomes.
https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01819-z
5. A Comparison of Mesenchymal Stromal Cells and MAP Cells:
Data would suggest that the immunomodulatory and cytoprotective capacity of MAPC is equivalent to that of MSC, and that MAPC may have superior angiogenic and broader differentiation properties. In practical terms, MAPC offer the distinct advantage over classical MSC that they can be produced on a large scale, in a reproducible manner.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724467/
6. MAPC® cell therapy enhances the ex-vivo expansion of polyclonal, regulatory T cells:
ReGenesys has developed a platform technology for the expansion of Treg cells derived from PB while fully maintaining their functional characteristics. This platform is based on the use of our proprietary MAPC stromal stem cell therapy which consists of non-hematopoietic stem cells derived from bone marrow that secrete various growth factors and have potent immunomodulatory effects. When CD4+CD25+127low-sorted Treg cells from PB were expanded on MAPC cells, a robust and high Treg cell yield was obtained, reaching the critical threshold of clinical batch production (1 billion cells) in all donors. Furthermore, a higher purity was observed (less potential CD8+ T cell contamination) and a specific signature was seen in terms of phenotype (low skin-homing/ high gut-homing marker expression). The immunosuppressive function was confirmed in both in vitro and in vivo models. Finally, successful Treg expansions have also been performed from PB of Crohn's Disease patients.
https://www.sciencedirect.com/science/article/pii/S1465324920303315
Novel delivery of cellular therapy to reduce ischaemia reperfusion injury in kidney transplantation:
The MAPC cells used in this study were obtained in collaboration with Athersys Inc, Ohio, and were provided as pre-dosed cryovial aliquots of 25x106 cells. This is the first reported series of cell therapy successfully delivered directly to human donor kidneys in an isolated ex vivo perfusion platform. Kidneys treated with MAPC cells during NMP demonstrate improvement in clinically relevant functional parameters and a reduction in injury and pro-inflammatory biomarkers. This is a paradigm shift, providing an exciting opportunity to directly treat organs prior to transplantation to minimise ischaemia reperfusion injury. A future clinical trial evaluating this modality of delivery could result in the transplantation of otherwise discarded organs, thereby reducing the transplant waiting list and offering hope to patients with renal failure.
https://www.medrxiv.org/content/10.1101/19005546v1.full.pdf
Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19:
Anti-inflammatory therapies for patients with ARDS have been developed using stem cells offering a great promise for managing ARDS. MSCs related cell-therapies demonstrate high efficacy in preclinical data allowing their clinical usage. The MCC950 molecule could affect the binding of SARS-CoV-2 to cells and inhibit the amplification of the intracellular virus, and also the ComC inhibitors that assist in modulating the activity of the innate immune system [93]. Another possible inhibition therapy against SARS-CoV-2 is the use of ACE2 + MSC-derived small extracellular vesicles (sEVs) overexpressed, as suggested by Inal.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442550/
FLDM just got their EUA FDA approval and having a nice price movement. They filed in mid June. T2 filed end of June within 2 weeks EUA FDA will send T2 200-300% higher .. GOOD LUCK LONGS
Everyone has there own reasons/needs to enter or exit their positions at any given moment in time, I will offer this to those who are not aware, Kenneth H. Traub, ATHX Director purchased 140k shares on or about 6/24 at an average cost of $2.30, totaling $322,000, I personally don't mind adding at a lower basis than Mr. Traub Harvard Business School MBA, to each his own GLTA!
Kenneth H. Traub, 58, currently serves as the Managing Member of the General Partner of Delta Value Group Investment Partnership, LP, an investment firm, since September 2019. Mr. Traub also currently serves as Chairman of the board since 2017 and on the board of directors since 2012 of DSP Group, Inc. (NASDAQ: DSPG), a leading global provider of chipsets for voice and wireless communications. Mr. Traub also currently serves on the board of directors of Tidewater, Inc., (NYSE: TDW), a global provider of vessels for the offshore drilling industry, since 2018. From December 2015 to January 2019, Mr. Traub was a Managing Partner at Raging Capital Management, LLC, an investment firm. From 2009 through 2015, Mr. Traub was President and Chief Executive Officer of Ethos Management LLC. From 1999 until its acquisition by JDS Uniphase Corp. ("JDSU") in 2008, Mr. Traub served as President and Chief Executive Officer of American Bank Note Holographics, Inc. ("ABNH"), a leading global supplier of optical security devices for the protection of documents and products against counterfeiting. Following the sale of ABNH, he served as Vice President of JDSU, a global leader in optical technologies and telecommunications. In 1994, Mr. Traub co-founded Voxware, Inc., a pioneer in voice over Internet protocol communication technologies, and served as its Executive Vice President and Chief Financial Officer through 1998. From 1988 to 1994, he served as Vice President of Trans-Resources, Inc., a multi-national holding company and investment manager. He previously served on the boards of directors of the following public companies: (i) Phoenix Technologies, Inc., a supplier of the basic input-output system for the personal computer industry, from 2009 until the company was sold in 2010, (ii) iPass, Inc., a provider of mobility services for Enterprises and Carriers, from 2009 to 2013, (iii) MIPS Technologies, Inc., a leading provider of industry standard processor architectures and cores, from 2011 until the company was sold in 2013, (iv) Xyratex Limited, a leading supplier of data storage technologies, from 2013 until the company was sold in 2014, (v) Vitesse Semiconductor Corporation, a leading supplier of integrated circuit solutions for next-generation carrier and enterprise networks, from 2013 until the company was sold in 2015, (vi) A. M. Castle & Co., a specialty metals and plastics distribution company from 2014 to 2016, (vii) Chairman of the board of MRV Communications, Inc., a provider of packet and optical communications network equipment, from 2011 until the company was sold in 2017, (viii) IDW Media Holdings, a diversified media company, from 2015 to 2018 and (ix) Gulfmark, Inc., a global provider of vessels for the offshore drilling industry, from 2017 until Gulfmark merged with Tidewater in 2018, (x) Immersion Corporation (NASDAQ: IMMR), a leading provider of haptics technology, from 2018 to 2019, and (xi) Intermolecular, Inc., an innovator in materials sciences, from 2016 until the Company was sold in 2019 and where Mr. Traub served as Chairman from 2018 until the sale. He also served as the Chairman of the Board of the NJ chapter of the Young Presidents Organization and on the board of the NJ chapter of the World Presidents Organization since 2012. Mr. Traub received a BA from Emory College and an MBA from Harvard Business School. We believe Mr. Traub’s qualifications to serve on our board include his extensive experience and expertise in managing and growing companies to maximize shareholder value and can contribute to the board’s effectiveness in strategic, financial, operational and governance matters. Mr. Traub previously served as a director of Athersys from 2012 to 2016 .. GOOD LUCK LONGS
Just up dating old news TTOO a leader in the rapid detection of sepsis-causing pathogens, reportedly announced a financial results for the second quarter ended June 30, 2020. However, many retailers around the country are said to race the supply shelves to keep up with CBD demand! If you want to know more, check this: http://psce.pw/UnderValuedCompanyHuntingTime
Investors with an interest in Medical stocks are advised to continue to track TTOO for the stock looks to great with its' solid performance. Also, this company moves aggressively in supplying thermal imaging technology against COVID-19. See This: https://shr.link/ThermalDroneTech
I also believe T2 will be a key part in the plasma treatment process. They need to make sure the plasma from COVID recovered donors is “clean” before using them on patients. Fast and accurate diagnostic from TTOO panels .. GOOD LUCK LONGS
Just a preview what is up and coming. The doctor also mentions stem cells to help people with covid !!!
https://video.foxnews.com/v/6183789502001#sp=show-clips
This could be the game changer regarding Multistem one can only hope ..
https://www.foxnews.com/politics/trump-to-reveal-coronavirus-breakthrough-therapeutic-wh-press-secretary-says
T2 has been in talks daily with the FDA and have been assigned their own agent. Things have been slightly delayed 30 days so pretty much July stuff has now turned into August goals so on take a look at 250k to 500k shares being bought in chunks at times from insiders and large corporations. This stock will be a money maker especially in a very short term time period worse comes to worse could be the end of September or early October at the latest. Between all the hiring there doing, constant sales reps and reports, assigned their own FDA agent and in talks with them daily use your own common sense .. GOOD LUCK LONGS
MULTIPOTENT ADULT PROJENITOR CELLS FOR TREATMENT OF ICH
Document Type and Number:
United States Patent Application 20200246390 Kind Code: A1
Abstract: Aspects of inventions herein described relate to administration of multipotent adult progenitor cells for treating intracerebral hemorrhage. Another Multi Billion dollar indication, hello big pharma … GOOD LUCK LONGS
It Seems EUA and FDA approval is imminent in the coming days. We should move above $2.50 with news. This is a LONG TERM hold with Sepsis and lyme treatments will be supporting this stock. Next year this should be trading above $10 its a Very Strong Company especially with the products they have. Investing in TTOO is a no brainer … GOOD LUCK LONGS
A week ago Healios reported enrollment completed for COVID-19 cohort .. Today Healios was up over 5.80% significantly out performed the broader Nikkei Index .26% Two events correlated and we will soon find out !! Also the news on Aug 12th from Japan that
our partner @HealiosJapan announced that it has completed enrollment of the #COVID19 induced #ARDS patient cohort which is part of its larger ONE-BRIDGE clinical trial to evaluate the safety of #MultiStem® cell therapy in ARDS.
https://ssl4.eir-parts.net/doc/4593/tdnet/1874762/00.pdf
This is rated a strong buy with several analyst .. Plus T2 Institutional Ownership and Insider Ownership 148 Million share outstanding with around 17% Institutional Ownership .. T2 is a long term hold. This should be above $5-$6 next year or more. Once the PR'S start hitting it will jump high and the SHORTS will get killed and RUN. Bottom line use your own common sense it has MORE UPSIDE than DOWNSIDE … GOOD LUCK LONGS
Gil and company likes keeping INFO close to their vest. ATHX has the best Management Team headed by GVB on the entire Wall Street. I am truly looking for great things happening here very soon. The reason being after hearing the conference call. They knew BARDA had been on hold after the funds had been diverted to other therapies that would be more immediately politically and like vaccines and antivirals that prevent disease. Multistem is indicated for patients who are about to be intubated and on a ventilator, less bang for the buck. Gil seems like a straight shooter, doesn't embellish the science or the path to commercialization. They will sooner or later advance this therapy to treat the several illnesses that it is indicated for and it is not just the Covid moment .. GOOD LUCK LONGS
There's more happening according to The SEC filing on August/14 BlackRock added 1,028,294 shares Vanguard Group inc added 2,712,336 shares Nothern Trust added 136,077 shares and the list goes on. Source: https://fintel.io/so/us/ttoo .. And let's not forget that the Medicare reimbursement for a sepsis test is $96. Hope they have enough people in the office to handle all the paperwork for the rest of the year .. GOOD LUCK LONG
Something to think about that State Street has taken a huge position and other Big Intituitions are increasing their shares too... State Street Reports 321.23% Increase In Ownership To Nearly 12M Shares August 14, 2020 - State Street Corp has filed a 13F-HR form disclosing ownership of 11,938,428 shares of Athersys, Inc. (US:ATHX) with total holdings valued at $32,950,000 USD as of June 30, 2020. .. GOOD LUCK LONGS